Dicerna Pharma (DRNA) Reports Q1 Loss of $0.38/Share

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. AMGN
3. BKNG
4. DOX
5. DUOL
6. ANET
7. SWKS
8. SPY
9. XYZ
10. FISV

Go back to Dicerna Pharma (DRNA) Reports Q1 Loss of $0.38/Share

Dicerna™ Reports First Quarter 2019 Financial and Operating Results and Provides Corporate Update

May 9, 2019 4:05 PM EDT

Initiated Screening of Participants to Enroll in the PHYOX2 Phase 2 Pivotal Trial of DCR-PHXC for the Treatment of Primary Hyperoxaluria (PH) and Announced Updated Data from Ongoing PHYOX1 Phase 1 of DCR-PHXC

Dosed First Healthy Volunteer in Phase 1 Clinical Trial of DCR-HBVS for Treatment of Chronic Hepatitis B Virus (HBV) Infection

Advanced Boehringer Ingelheim Collaboration with Exercise of Option for Second Hepatic Disease Target for Non-Alcoholic Steatohepatitis (NASH) and Other Chronic Liver Diseases

Management to Host Conference Call Today at 4:30 p.m. ET 

CAMBRIDGE, Mass.--(BUSINESS WIRE)--... More